

Table of Contents

1	Introduction	7
2	Acknowledgements	9
2.1	Acknowledgment to Contributing Authors	9
2.2	Acknowledgment to Reviewers	9
3	Regulatory/GxP Information	11
	Common Technical Document	
3.1	Critical Learning Points	11
3.2	Background, Depth, and Breadth Information	11
3.3	References	13
	cGMPs and their Relevance to Clinical Materials	
3.4	Critical Learning Points	13
3.5	Background, Depth, and Breadth Information	14
3.6	References	20
	New EU Regulatory Environment - Implications for Clinical Supplies Management	
3.7	Critical Learning Points	21
3.8	Background, Depth, and Breadth Information	22
3.9	References	28
4	Project Planning and Management and Clinical Trial Design	29
	Study Protocols	
4.1	Critical Learning Points	29
4.2	Background, Depth, and Breadth Information	29
4.3	References	31
	Randomizations	
4.4	Critical Learning Points	31
4.5	Background, Depth, and Breadth Information	31
4.6	References	35
	Project Management	
4.7	Critical Learning Points	36
4.8	Background, Depth, and Breadth Information	36
4.9	References	38
	Process Improvement	
4.10	Critical Learning Points	38
4.11	Background, Depth, and Breadth Information	39
4.12	References	41
5	Manufacturing	43
	Equipment/Facilities Qualification/Verification/Validation	
5.1	Critical Learning Points	43
5.2	Background, Depth, and Breadth Information	43
5.3	References	45

Cleaning Verification/Validation	
5.4	Critical Learning Points 45
5.5	Background, Depth, and Breadth Information 46
5.6	References 49
Manufacturing Process Containment	
5.7	Critical Learning Points 50
5.8	Background, Depth, and Breadth Information 51
5.9	References 53
Parenteral Product Manufacturing	
5.10	Critical Learning Points 53
5.11	Background, Depth, and Breadth Information 54
5.12	References 56
Radio-Labeled Clinical Trial Material	
5.13	Critical Learning Points 57
5.14	Background, Depth, and Breadth Information 58
5.15	References 60
Controlled Substances/Drugs	
5.16	Critical Learning Points 61
5.17	Background, Depth, and Breadth Information 62
5.18	References 64
Comparator Drugs and Blinding Considerations	
5.19	Critical Learning Points 65
5.20	Background, Depth, and Breadth Information 66
5.21	References 71
Packaging and Labeling Considerations	
5.22	Critical Learning Points 72
5.23	Background, Depth, and Breadth Information 72
5.24	References 82
6	Distribution and Returns 83
Clinical Material Distribution	
6.1	Critical Learning Points 83
6.2	Background, Depth, and Breadth Information 83
6.3	References 84
Strategies for Limited Drug Availability	
6.4	Critical Learning Points 85
6.5	Background, Depth, and Breadth Information 85
6.6	References 86
Interactive Voice Response System (IVRS)	
6.7	Critical Learning Points 86
6.8	Background, Depth, and Breadth Information 87
6.9	References 93
Cold Chain Control and Shipping Validation	
6.10	Critical Learning Points 96
6.11	Background, Depth, and Breadth Information 96
6.12	References 97

U.S. Import/Export Considerations	
6.13	Critical Learning Points 97
6.14	Background, Depth, and Breadth Information 98
6.15	References 102
Returns and Reconciliation	
6.16	Critical Learning Points 102
6.17	Background, Depth, and Breadth Information 103
6.18	References 104
7	Definitions 105
	References 114

